How should overactive bladder be managed?

Management of Overactive Bladder

Start with patient education and behavioral therapies, then offer β3-agonists (mirabegron) as first-line pharmacotherapy before antimuscarinics, and consider minimally invasive procedures (sacral neuromodulation, tibial nerve stimulation, or botulinum toxin) early through shared decision-making without requiring failure of conservative measures. 1

Initial Evaluation

Perform these three essential steps 1:

• Medical history: Focus on urgency (the defining symptom), frequency, nocturia, incontinence episodes, fluid intake, caffeine/alcohol use, and impact on quality of life
• Physical examination: Assess for pelvic organ prolapse, neurological deficits, and abdominal masses
• Urinalysis: Rule out infection and hematuria (perform urine culture if either is present)

Telemedicine is acceptable for initial evaluation if urinalysis can be obtained at a local laboratory, though in-office follow-up is needed for non-responders 1.

Treatment Framework: Menu-Based Approach

The 2024 AUA/SUFU guidelines fundamentally changed OAB management by abandoning rigid stepwise progression in favor of a menu-based system where patients select treatments based on their preferences, not invasiveness 1. This addresses the reality that compliance with behavioral therapy and first-line medications is poor, leaving many patients frustrated.

First-Line Options (Can Be Combined)

Behavioral Therapies 1:

• Timed voiding schedules
• Urgency suppression techniques
• Fluid management (avoid excessive intake)
• Eliminate bladder irritants (caffeine, alcohol)
• Treat contributing conditions: constipation, obesity, diabetes, benign prostatic hyperplasia, genitourinary syndrome of menopause

Non-Invasive Therapies 1:

• Pelvic floor muscle training with biofeedback
• Transcutaneous tibial nerve stimulation

Pharmacotherapy

β3-Agonists (Mirabegron) Should Be Tried Before Antimuscarinics 1. This represents a major shift from historical practice.

Start mirabegron 25-50 mg daily 2:

• Use 25 mg in elderly patients, those with low detrusor contractility, CNS lesions, or men with BPH
• Increase to 50 mg if 25 mg is insufficient
• Safer profile for patients at risk of cognitive dysfunction, constipation, dry mouth, or urinary retention 2

Antimuscarinics (oxybutynin, tolterodine, solifenacin, darifenacin, trospium) 1:

• Critical warning: Three case-control studies found antimuscarinics increase risk of all-cause dementia and Alzheimer's disease—consider cognitive risks in all patients for chronic use 1
• Contraindications requiring extreme caution: narrow-angle glaucoma, impaired gastric emptying, history of urinary retention 1
• Additional caution in diabetes, prior abdominal surgery, narcotic use, scleroderma, hypothyroidism, Parkinson's disease, multiple sclerosis 1

Combination Therapy: For patients refractory to monotherapy with either β3-agonist or antimuscarinic, combine both drug classes 3, 4, 2. This provides superior efficacy compared to switching medications.

Minimally Invasive Therapies

These can be offered WITHOUT requiring trials of behavioral or pharmacologic therapy 1. This is expert opinion-based but reflects high success rates, durable efficacy, and excellent patient satisfaction.

For inadequate response or intolerable side effects from pharmacotherapy 1:

• Sacral neuromodulation (SNM)
• Percutaneous or implantable tibial nerve stimulation (PTNS)
• Intradetrusor botulinum toxin injection (100 units) 4
  • Patients must be willing to perform clean intermittent self-catheterization if retention occurs

All three options effectively reduce voiding frequency, nocturia, urgency episodes, and incontinence 1.

Common Pitfalls

Don't force stepwise progression: The evidence shows patients abandon treatment when forced through ineffective therapies. Offer the full menu early 1.

Don't ignore cognitive risks with antimuscarinics: The dementia association is real—document this discussion and prefer β3-agonists for chronic use 1.

Don't overlook comorbidities: Optimize BPH, constipation, diabetes, and obesity as these directly worsen OAB 1.

PTNS limitation: Requires repeated in-office treatments, creating treatment burden 1.

When to Investigate Further

Consider urodynamics, cystoscopy, or imaging if 1, 5:

• Hematuria present
• Pelvic mass detected
• Predominant voiding symptoms (not storage symptoms)
• Pelvic pain
• Neurological disease
• Atypical symptoms
• Inadequate response to treatment